A Novel Solid Lipid Nanoparticle Formulation for Active Targeting to Tumor αvβ3 Integrin Receptors Reveals Cyclic RGD as A Double‐Edged Sword

The overexpression of α(v) β(3) integrin receptors on tumor cells and tumor vascular endothelium makes it a useful target for imaging, chemotherapy and anti-angiogenic therapy. However integrin-targeted delivery of therapeutics by nanoparticles have provided only marginal, if any, enhancement of therapeutic effect. This work was thus focused on the development of novel α(v) β(3) -targeted near infrared light-emitting solid lipid nanoparticles (SLN) through conjugation to the α(v) β(3) integrin-specific ligand cyclic Arg-Gly-Asp (cRGD), and the assessment of the effects of α(v) β(3) targeting on nanoparticle biodistribution. Since our previously developed non-targeted "stealth" SLN showed little hepatic accumulation, unlike most reported liposomes and micelles, they served as a reference for quantifying the effects of cRGD-conjugation on tumor uptake and whole animal biodistribution of SLN. Non-targeted SLN, actively targeted (RGD-SLN) and blocked RGD-SLN were prepared to contain near infrared quantum dots for live animal imaging. They were injected intravenously to nude mice bearing xenograft orthotopic human breast tumors or dorsal window chamber breast tumors. Tumor micropharmacokinetics of various SLN formulations were determined using intravital microscopy, and whole animal biodistribution was followed over time by optical imaging. The active tumor targeting with cRGD was found to be a "double-edged sword": while the specificity of RGD-SLN accumulation in tumor blood vessels and their tumor residence time increased, their distribution in the liver, spleen, and kidneys was significantly greater than the non-targeted SLN, leaving a smaller amount of nanoparticles in the tumor tissue. Nevertheless the enhanced specificity and retention of RGD-SLN in tumor neovasculature could make this novel formulation useful for tumor neovascular-specific therapies and imaging applications.

[1]  L. Knight,et al.  Radiation-Guided Targeting of Combretastatin Encapsulated Immunoliposomes to Mammary Tumors , 2009, Pharmaceutical Research.

[2]  Christine Allen,et al.  In Vivo Distribution of Polymeric Nanoparticles at the Whole-Body, Tumor, and Cellular Levels , 2010, Pharmaceutical Research.

[3]  X. Wu,et al.  Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[4]  S. Liu,et al.  Lead distribution in blood and organs of mice exposed to lead by vein injection , 2009, Environmental technology.

[5]  R. Schiffelers,et al.  Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[6]  Christine Allen,et al.  The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles. , 2010, Molecular pharmaceutics.

[7]  Ricardo H Álvarez,et al.  Present and future evolution of advanced breast cancer therapy , 2010, Breast Cancer Research.

[8]  Vladimir P Torchilin,et al.  Passive and active drug targeting: drug delivery to tumors as an example. , 2010, Handbook of experimental pharmacology.

[9]  David A. Cheresh,et al.  Integrins in cancer: biological implications and therapeutic opportunities , 2010, Nature Reviews Cancer.

[10]  Michael C. Kolios,et al.  Hybrid quantum dot-fatty ester stealth nanoparticles: toward clinically relevant in vivo optical imaging of deep tissue. , 2011, ACS nano.

[11]  B. Neustadt,et al.  Targeting integrins alpha v beta 3 and alpha v beta 5 for blocking tumor-induced angiogenesis. , 2000, Advances in experimental medicine and biology.

[12]  M. Humphries,et al.  Dual Functionality of the Anti-β1 Integrin Antibody, 12G10, Exemplifies Agonistic Signalling from the Ligand Binding Pocket of Integrin Adhesion Receptors* , 2005, Journal of Biological Chemistry.

[13]  E Ruoslahti,et al.  Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion. , 1987, The Journal of biological chemistry.

[14]  Qiang Zhang,et al.  Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[15]  Milan Makale,et al.  Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis , 2008, Proceedings of the National Academy of Sciences.

[16]  P. Delmas,et al.  Expression of thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast. , 1993, Cancer research.

[17]  S. Goodman,et al.  Structural and Functional Aspects of RGD-Containing Cyclic Pentapeptides as Highly Potent and Selective Integrin αVβ3 Antagonists , 1996 .

[18]  Y. Kishimoto,et al.  Esterification of fatty acids at room temperature by chloroform-methanolic HCl-cupric acetate. , 1973, Journal of lipid research.

[19]  J. Manias,et al.  A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells , 2008, Breast Cancer Research and Treatment.

[20]  X. Wu,et al.  In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[21]  R. Schiffelers,et al.  Peptide-targeted PEG-liposomes in anti-angiogenic therapy. , 2003, International journal of pharmaceutics.

[22]  S. Kitazawa,et al.  Integrin αvβ3 Expression by Bone‐residing Breast Cancer Metastases , 1996 .

[23]  Brian C. Wilson,et al.  Homogenized tissue phantoms for quantitative evaluation of subsurface fluorescence contrast. , 2011, Journal of biomedical optics.

[24]  W. Chui,et al.  Integrin targeted drug and gene delivery , 2010, Expert opinion on drug delivery.

[25]  Zhiyuan Hu,et al.  Arg-Gly-Asp (RGD) peptide conjugated poly(lactic acid)-poly(ethylene oxide) micelle for targeted drug delivery. , 2008, Journal of biomedical materials research. Part A.

[26]  J Szebeni,et al.  Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. , 2003, Progress in lipid research.

[27]  P. Workman.  Micropharmacokinetics of chemical modifiers. , 1989, International journal of radiation oncology, biology, physics.

[28]  Theresa M Allen,et al.  Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. , 2004, Biochimica et biophysica acta.

[29]  Garry E. Kiefer,et al.  Imaging of Vx‐2 rabbit tumors with ανβ3‐integrin‐targeted 111In nanoparticles , 2007 .

[30]  Y. Yarden,et al.  Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. , 1996, British Journal of Cancer.

[31]  P. Carmeliet.  Mechanisms of angiogenesis and arteriogenesis , 2000, Nature Medicine.

[32]  U. Nielsen,et al.  Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. , 2006, Cancer research.

[33]  Sevim Z. Erhan,et al.  A New Polymer–Lipid Hybrid Nanoparticle System Increases Cytotoxicity of Doxorubicin Against Multidrug-Resistant Human Breast Cancer Cells , 2006, Pharmaceutical Research.

[34]  N. Hogg,et al.  Vitronectin receptor-mediated phagocytosis of cells undergoing apoptosis , 1990, Nature.

[35]  T. Krauss,et al.  Ultrabright PbSe magic-sized clusters. , 2008, Nano letters.

[36]  B. Neustadt,et al.  Targeting Integrins αvβ3 and αvβ5 for Bloking Tumor-Induced Angiogenesis , 2000 .

[37]  Sanyog Jain,et al.  Liposomes Modified with Cyclic RGD Peptide for Tumor Targeting , 2004, Journal of drug targeting.

[38]  R. Weissleder,et al.  Multivalent effects of RGD peptides obtained by nanoparticle display. , 2006, Journal of medicinal chemistry.

[39]  X. Wu,et al.  A Mechanistic Study of Enhanced Doxorubicin Uptake and Retention in Multidrug Resistant Breast Cancer Cells Using a Polymer-Lipid Hybrid Nanoparticle System , 2006, Journal of Pharmacology and Experimental Therapeutics.

[40]  Manfred Schwab,et al.  Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. , 2002, Cancer research.

[41]  Dai Fukumura,et al.  Dissecting tumour pathophysiology using intravital microscopy , 2002, Nature Reviews Cancer.

[42]  V. Torchilin,et al.  The architecture of ligand attachment to nanocarriers controls their specific interaction with target cells , 2008, Journal of drug targeting.

[43]  H. Wong,et al.  Tailoring nanostructured solid-lipid carriers for time-controlled intracellular siRNA kinetics to sustain RNAi-mediated chemosensitization. , 2011, Biomaterials.

[44]  R K Jain,et al.  Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. , 1999, Cancer research.